A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.

Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia, and affect the cardiovascular system, central nervous system and the renal system, resulting in hospitalization and death risks in children and also high-risk adults, particularly the elderly. The purpose of this study is to evaluate the efficacy of Ziresovir (AK0529) compared to placebo with respect to the time to resolution of RSV lower respiratory tract disease (LRTD) symptoms.

开始日期2026-03-03

申办/合作机构

上海爱科百发生物医药技术股份有限公司

NCT06591845

/ Completed临床1期

A Single-Center, Randomized, Partially Double-Blind, Placebo- and Active-Controlled, Four-period Crossover, Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy subjects.

开始日期2024-09-25

申办/合作机构

上海爱科百发生物医药技术股份有限公司

NCT06775405

/ Recruiting临床3期

A Randomized, Double-blind, Placebo-controlled, Phase III Confirmatory Study to Evaluate the Efficacy, Safety, Tolerability, and Antiviral Activity of Repeated Oral Administration of AK0529 in Hospitalized Infants with Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in infants. Serious respiratory problems such as pneumonia caused by RSV are one of the leading causes of death from respiratory diseases in infants. AK0529 targets the Pre-F (fusion) protein on the surface of the viral envelope. Specifically, it prevents the virus from invading uninfected cells and inhibits the fusion between host cells by inhibiting the fusion of the F (fusion) proteins on the surface of the RSV envelope, thus providing the effects of anti-RSV infection. This is a randomized, double-blind, placebo-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of AK0529 in hospitalized infants aged 1 to 24 months with RSV infection. Considering the benefits of AK0529 in the population with RSV infection, hospitalized infants with moderate to severe RSV infection were selected as the target population for this study.

开始日期2024-02-29

申办/合作机构

上海爱科百发生物医药技术股份有限公司

100 项与齐瑞索韦相关的临床结果

登录后查看更多信息

100 项与齐瑞索韦相关的转化医学

登录后查看更多信息

100 项与齐瑞索韦相关的专利（医药）

登录后查看更多信息

项与齐瑞索韦相关的文献（医药）

2026-06-01·LIFE SCIENCES

Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation

Article

作者: Chen, Weiyi ; Go, Yun Young ; Shin, Jin Soo ; Yeh, Jung-Yong ; Chen, Zhenhai ; Zhou, Bin ; Jung, Eunhye ; Ji, Min Chae

Waning vaccine-derived immunity and the emergence of new SARS-CoV-2 subvariants continue to challenge global public health, emphasizing the need for novel inhibitors against SARS-CoV-2 infection. Molecular inhibitors targeting virus entry are promising candidates as they can disrupt viral replication at the earliest stage. In this study, we utilized a fluorescence-based SARS-CoV-2 pseudovirus screening platform to identify entry inhibitors from a repurposed library of bioactive compounds. Ziresovir and TMC353121, both small molecules known as respiratory syncytial virus (RSV) fusion inhibitors, were identified as hits that inhibited SARS-CoV-2 pseudovirus entry. In vitro and in silico analyses, together with site-directed mutagenesis, demonstrated that these molecules interfere with the formation of the six-helix bundle (6HB) in the SARS-CoV-2 spike (S) protein, thereby inhibiting membrane fusion. Additionally, both compounds exhibited inhibitory effects against SARS-CoV pseudovirus, wild-type SARS-CoV-2, and several other coronaviruses. These findings identify Ziresovir and TMC353121 as mechanistically validated scaffolds that target conserved fusion mechanisms across different viral families. While further optimization is required to enhance their potency against infectious SARS-CoV-2, this study provides a strategic foundation and chemical templates for the development of broad-spectrum fusion inhibitors to combat current and future coronavirus threats.

2026-02-01·RESPIRATORY MEDICINE

Respiratory syncytial virus in high-risk adults: A critical appraisal of therapeutic options and unmet needs

Review

作者: Ranellou, Kyriaki ; Panagiotopoulos, Antonios-Periklis ; Anastassopoulou, Cleo ; Mariolis, Ilias ; Tsakris, Athanasios

Respiratory syncytial virus (RSV) has traditionally been viewed as a causative agent of pediatric illness, yet accumulating evidence shows substantial morbidity and mortality among adults, particularly older individuals, those with cardiopulmonary comorbidities, and the immunocompromised. Although recent vaccine approvals for older adults represent major progress in prevention, effective therapeutic options for established infection remain limited. Herein we provide a critical analysis of existing and emerging antiviral and monoclonal antibody (mAb) therapies for the management of RSV infection in adults, highlighting current options and compounds in clinical development. At present, ribavirin remains the only antiviral recommended for treatment in adults, and no mAb has received regulatory authorization for prophylaxis or therapy in this population. Several development programs for direct-acting antivirals have been discontinued for reasons unrelated to safety or efficacy in adults, contributing to an ongoing treatment gap. Nevertheless, newer drug candidates, including ziresovir, EDP-938, and S-337395, have shown encouraging antiviral activity and acceptable safety in adult studies. By examining both the scientific evidence and the structural factors shaping the current landscape, we emphasize the need for sustained adult-focused clinical development to complement preventive vaccination. Addressing this therapeutic gap will be essential to reduce the burden of RSV disease in high-risk adult populations, particularly as the global population ages.

2025-12-02·Expert Opinion on Drug Discovery

Synthetic oxetanes in drug discovery: where are we in 2025?

Review

作者: Bull, James A. ; Ishikura, Hikaru

INTRODUCTION:

Oxetanes are increasingly prevalent motifs in medicinal chemistry. While oxetanes feature famously in the taxol family, it was not until the recent approval of rilzabrutinib that they have been validated in a fully synthetic drug. These four-membered oxygen-containing rings are valued for their ability to modulate key physicochemical properties such as polarity, lipophilicity, and metabolic stability. Their incorporation can improve aqueous solubility, reduce metabolic liability, reduce basicity of adjacent amines, and redirect metabolic clearance away from cytochrome P450 enzymes.

AREAS COVERED:

This review examines the role of the oxetane in nine clinical candidates, one very recently approved, two recently discontinued clinical candidates, two tool compounds, and three lead compounds disclosed in 2024. Recent advances indexed in SciFinder-n (2017-2024) in the process-scale and laboratory-scale synthetic routes are discussed, highlighting ongoing innovation required to access these motifs efficiently and sustainably.

EXPERT OPINION:

The regulatory approval of rilzabrutinib and likely approval of ziresovir provide confidence in using oxetanes as important elements in drug design. While oxetanes have so far been incorporated primarily as pendant groups to optimize physicochemical properties, their use as scaffolding and binding elements presents an exciting opportunity. Enhanced synthetic accessibility to oxetane derivatives will expedite their inclusion in drug discovery campaigns.

207

项与齐瑞索韦相关的新闻（医药）

2026-08-19

·PRNewswire

ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis

SHANGHAI, Aug. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug to enter clinical development in China. AK0406 is a new generation, long-acting antiviral agent discovered and developed by ArkBio. By precisely conjugating a highly potent antiviral small molecule with an antibody Fc fragment, AK0406 is designed to provide sustained pre‑ and post‑exposure prophylaxis and potential therapeutic benefits, addressing the high unmet needs for influenza prevention during peak seasons. Preclinical data show that AK0406 exerts broad-spectrum, high-potency activity against both influenza A and B viruses, maintains immune effector function, and provides prolonged exposure. Compared with other AFC molecules, AK0406 is engineered to offer an optimized profile for both prophylaxis and treatment of influenza infection. On the global clinical development front, ArkBio received approval from the Australian Human Research Ethics Committee (HREC) in February 2026 to initiate a phase I clinical trial of AK0406. Enrollment and dosing of healthy adult volunteers in all cohorts have been completed in Australia, and the trial has now entered the follow-up phase. Influenza remains a critical global public health challenge. Current flu preventive measures centered on seasonal vaccines face significant limitations, including the inability to effectively address antigenic drift, uncertainty in annual strain prediction and matching, and substantially reduced protective efficacy among elderly and immunocompromised populations, leaving significant unmet clinical needs. ArkBio will maintain close interactions with the CDE to advance the clinical development of AK0406 in China, while continuing the follow-up work of the ongoing phase I study in Australia. By pursuing a parallel, dual‑track development pathway in China and globally, the company aims to accelerate the clinical program to deliver a safer, more effective, and convenient solution for influenza prevention worldwide. About ArkBio ArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations. Key pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral for RSV with positive pivotal phase 3 results; AK3280, a potentially best-in-class anti-fibrotic agent with positive phase 2 results in idiopathic pulmonary fibrosis, is currently in phase 3 registrational trials; AK0901, approved and commercialized in China for ADHD treatment. The company also has multiple first-in-class or best-in-class innovative candidates in clinical or preclinical development. ArkBio has established strategic partnerships with multinational pharmaceutical companies including Roche and Genentech, leading academic institutions including The Scripps Research Institute and the Institute of Microbiology of the Chinese Academy of Sciences, Qilu Pharmaceutical, as well as other domestic and international biotech companies and CROs. For more information, please visit: Investor Inquiries: [email protected] SOURCE Shanghai Ark Biopharmaceutical Co., Ltd. 21% more press release views with Request a Demo

临床3期临床1期临床申请临床结果临床2期

2026-08-18

·动脉网

艾科生物的RSV抗病毒药物Ziresovir获得FDA二期临床试验批准ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

SHANGHAI 上海, ，Aug. 14, 2026 2026年8月14日/PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced that the U.S. Food and Drug Administration (FDA) /美通社/ -- 上海阿科生物科技有限公司（“ArkBio”）今日宣布，美国食品药品监督管理局（FDA）has approved 已批准ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected infant patients, including the ones in pediatric intensive care unit (PICU). 齐雷索韦（AK0529）用于重症呼吸道合胞病毒（RSV）感染婴儿患者（包括儿科重症监护室 [PICU] 患者）的II期临床试验。Severe RSV Infection: An Urgent Unmet Need in PICU 严重呼吸道合胞病毒感染：儿科重症监护室中亟待满足的迫切需求RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing approximately 33 million LRTI cases, 3.6 million hospitalizations, and more than 100,000 deaths annually. Severely ill RSV infected infants often require admission to the PICU for intensive care such as respiratory support, with rapid disease progression, high risk and a heavy medical burden. 呼吸道合胞病毒（RSV）是全球婴幼儿下呼吸道感染（LRTIs）的首要病原体，每年导致约3,300万例下呼吸道感染病例、360万例住院以及超过10万例死亡。重症RSV感染婴儿往往需要入住儿科重症监护室（PICU）接受呼吸支持等强化治疗，其病情进展迅速、风险高，且医疗负担沉重。There is currently no approved RSV-specific antiviral therapy worldwide; clinical management remains limited to symptomatic and supportive care, such as oxygenation, leaving an urgent unmet need for effective antiviral treatment in hospitalized RSV infected patients with severe diseases.. 目前全球范围内尚无获批的呼吸道合胞病毒（RSV）特异性抗病毒疗法；临床管理仍仅限于氧疗等对症和支持治疗，因此住院的重症RSV感染患者对有效抗病毒治疗存在迫切的未满足需求。Ziresovir Advances to Treat Severely Infected Infant Patients 齐雷索韦在救治重症感染婴儿患者方面取得进展Ziresovir is the first direct RSV antiviral drug to successfully complete a phase III clinical trial with positive results. The clinical study in 1-24 months age patients conducted in China demonstrated that ziresovir can significantly reduce viral load, accelerate the resolution of respiratory symptoms, and significantly lower the risk of recurrent wheezing and asthma over 24-month follow-up period, with a favorable safety profile. Ziresovir 是首个在 III 期临床试验中取得阳性结果并成功完成的直接抗呼吸道合胞病毒（RSV）药物。在中国开展的针对 1-24 个月龄患者的临床研究显示，Ziresovir 能显著降低病毒载量，加速呼吸道症状的缓解，并在 24 个月的随访期内显著降低复发性喘息和哮喘的风险，且安全性良好。Key findings from the clinical study have been published in . 该临床研究的主要发现已发表于。The New England Journal of Medicine 《新英格兰医学杂志》and 和The Lancet Child & Adolescent Health 《柳叶刀·儿童与青少年健康》. In 2025, ziresovir was included as the only therapeutic drug in the WHO's Paediatric Drug Optimization for Respiratory Syncytial Virus publication. The newly approved phase II clinical trial marks the extension of ziresovir's clinical development into the most critically ill RSV patients, representing a key milestone in the clinical development of ziresovir globally.. 2025年，齐雷索韦（ziresovir）作为唯一的治疗药物被纳入世界卫生组织发布的《呼吸道合胞病毒儿科药物优化》出版物中。新获批的II期临床试验标志着齐雷索韦的临床开发扩展至病情最危重的RSV患者群体，这代表了齐雷索韦在全球临床开发进程中的一个关键里程碑。FDA Approved Phase II Clinical Trial FDA批准的II期临床试验The approved multicenter, randomized, double-blind, placebo-controlled phase II clinical trial will focus on severely ill RSV infected infants requiring hospitalization in PICU, one of the most critical RSV patient populations with the most urgent clinical treatment needs. This clinical trial is designed to evaluate clinical efficacy of ziresovir, especially the length of oxygen treatment and sustained recovery time, providing the clinical basis for the future registrational trials.. 这项已获批准的多中心、随机、双盲、安慰剂对照的II期临床试验将聚焦于需要入住儿科重症监护室（PICU）的重症呼吸道合胞病毒（RSV）感染婴儿，这是RSV患者中病情最危重、临床治疗需求最迫切的人群之一。该临床试验旨在评估泽雷索韦（ziresovir）的临床疗效，特别是吸氧治疗时长和持续恢复时间，为未来的注册性临床试验提供临床依据。About ArkBio 关于 ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations.. ArkBio 是一家处于商业化阶段的生物技术公司，专注于发现和开发用于呼吸系统/肺部疾病及儿科疾病的创新疗法。公司成立于 2014 年，通过内部创新和战略合作，建立了专有技术平台和差异化的研发管线。Key pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral for RSV with positive phase 3 results; AK3280, a potentially best-in-class anti-fibrotic agent with positive phase 2 results in idiopathic pulmonary fibrosis, currently in phase 3 registrational trials; AK0901, approved and commercialized in China for ADHD treatment. 关键管线资产包括：ziresovir（AK0529），首款针对呼吸道合胞病毒（RSV）的直接作用抗病毒药物，其III期临床试验结果积极；AK3280，一种潜在的同类别最佳抗纤维化药物，在特发性肺纤维化治疗中II期临床试验结果积极，目前正处于III期注册性临床试验阶段；AK0901，已在中国获批上市并商业化，用于治疗注意力缺陷多动障碍（ADHD）。The company also has multiple first-in-class or best-in-class innovative drug candidates in clinical or preclinical development.. 该公司还拥有多个处于临床或临床前开发阶段的同类首创或同类最佳创新药候选药物。ArkBio has established strategic partnerships with multinational pharmaceutical companies including Roche and Genentech, leading academic institutions including The Scripps Research Institute and the Institute of Microbiology of the Chinese Academy of Sciences, Qilu Pharmaceutical, as well as other domestic and international biotech companies and CROs.. ArkBio已与罗氏和基因泰克等跨国制药公司，斯克里普斯研究所和中国科学院微生物研究所等领先学术机构，齐鲁制药，以及其他国内外生物科技公司和合同研究组织（CRO）建立了战略合作伙伴关系。For more information, please visit: 如需更多信息，请访问：www.arkbiosciences.com www.arkbiosciences.comInvestor Inquiries: 投资者咨询：[emailprotected] [email protected]SOURCE Shanghai Ark Biopharmaceutical Co., Ltd. 来源：上海阿科生物制药有限公司21 二十一% %more press release views with 更多新闻稿浏览量，借助Request a Demo 申请演示

2026-08-18

·求实药社

座无虚席！SIT 2026 第八届小分子药物创新峰会圆满落幕！

SIT 2026 2026年8月13-14日·中国南京由上海恺默信息咨询有限公司与求实药社主办的SIT 2026 第八届小分子药物创新峰会圆满落幕！ SIT 2026 第八届小分子药物创新峰会将于2026年8月13-14日在南京召开。本届峰会汇聚业内顶尖的化学药物专家，深入探讨小分子药物的创新路径，分享业内最前沿的技术与策略。会议设置CNS专题，与ICNS 2026第六届中枢神经系统药物深度聚焦论坛形成内容联动，共同推动中国创新药物研发的体系化突破。嘉宾集锦 - SIT·2026 - 8月13日小分子创新策略与突破进展演讲主题：基于AIDD创新管线药物的研发演讲嘉宾：朱永强，南京师范大学生命科学学院，教授、博士生导师演讲主题： First-in-disease RSV 治疗药物Ziresovir的发现演讲嘉宾：吕贺军，上海爱科百发新药研发副总裁，苏州爱科百发总经理演讲主题：通过集成无定形固体分散体与连续式压片制剂平台，加速难溶性原料药的口服递送演讲嘉宾： Dr. João Pires，好利安制药技术公司，吸入和高级药物递送研发总监演讲主题： The Discovery and Development of Girocitinib - a 3rd Generation JAK Inhibitor 演讲嘉宾：唐炜，杭州高光制药有限公司，资深副总裁演讲主题：疾病细胞虚拟病人：重构CiPA标准的NAMs in silico新路径演讲嘉宾：胡树铭，上海石指健康科技有限公司，创始人、董事长圆桌主题：超越内卷——小分子药物的差异化竞争与赛道选择策略圆桌嘉宾：刘为民，生物医药投资人吕贺军，上海爱科百发新药研发副总裁，苏州爱科百发总经理林凯，东阳光药，首席科学家胡柯，迈威生物，海外CMO 演讲主题：后GLP-1时代的口服减重药物CG-0416：减脂保肌, 降低副作用, 改善依从性！演讲嘉宾：陈小五，上海柯君医药，化学副总裁演讲主题：抗肿瘤创新药演讲嘉宾：吴鸣，浙江同源康医药股份有限公司，商务拓展&投资者关系副总裁演讲主题：剂型改良驱动的小分子药物创新演讲嘉宾：高庚，LTS Lohmann Therapie-Systeme AG , 亚洲总监演讲主题：非喜树碱类TOPO1抑制剂平台：解决现有ADC药物耐药问题演讲嘉宾：党群，河南真实生物科技有限公司，总裁演讲主题：处方前研究对新药开发的重要性演讲嘉宾：黄廉丰，晶云药物，首席科学家演讲主题：小分子药物创新：First-in-Class, First-in-Disease,and Best-in-Class思考和设计演讲嘉宾：沈旺，维眸生物科技（浙江）股份有限公司，CEO、董事长圆桌主题：决胜未来十年——小分子药物的新前沿、新战场圆桌嘉宾：汪俊，凌科药业，联合创始人、首席科学官粘瑜芝，罗氏制药全球合作部，亚太区商务拓展总监吴鸣，浙江同源康医药股份有限公司，商务拓展&投资者关系副总裁沈旺，维眸生物科技（浙江）股份有限公司，CEO、董事长夏广新，上海医药集团中央研究院副院长，创新免疫治疗全重实验室副主任陈小五，上海柯君医药，化学副总裁 8月14日下一代小分子技术前沿演讲主题：后GLP-1时代高安全性减重药物开发演讲嘉宾：宋文鑫，上海民为生物技术有限公司，副总经理，CSO 演讲主题：靶向GPR84：创新机制研究和临床开发演讲嘉宾：南发俊，博骥源（上海）生物医药有限公司，创始人&董事长演讲主题：信息学指导的新药研发演讲嘉宾：江磊，上海轶诺药业有限公司，CEO 演讲主题： Advanced Drug Discovery Powered by Puhe-APDD 演讲嘉宾：关慧平，浦合医药，CSO 演讲主题：类器官疾病模型驱动首个FAK/SRC双靶点抑制剂开发演讲嘉宾：张海生，希格生科（深圳）有限公司，创始人&CEO 演讲主题：解锁合成致死新机遇：高活性Polθ 抑制剂的发现与研究演讲嘉宾：贺虎，杭州圣域生物医药科技有限公司，副总裁演讲主题：聚焦转录因子及调控的变革性药物研发演讲嘉宾：丁元华，元启（苏州）生物制药有限公司，创始人&CEO 演讲主题： PROTAC 分子解决难成药性靶点问题演讲嘉宾：张兵，杭州多域生物技术有限公司，高级副总裁演讲主题： EBI2小分子拮抗剂治疗狼疮肾炎的临床前和临床研究演讲嘉宾：范国煌，南京艾美斐生物医药科技股份有限公司，创始人、董事长演讲主题：新一代高选择性PARP1抑制剂的发现及临床开发演讲嘉宾：魏毅，优领医药科技，药化负责人演讲主题：分子互作的动力学过程设计：AIDD的下一站演讲嘉宾：竺立哲，深圳睿陉生物科技有限公司，创始人&CTO 8月13日赛默飞创新药分析整体解决方案论坛欢迎致辞：余跃龙，赛默飞世尔科技色谱质谱地区销售经理演讲主题：赛默飞全新液相-高分辨质谱在生物制药研究中的新进展和方案演讲嘉宾：程汉兴，赛默飞世尔科技资深应用工程师演讲主题：重组多肽的抗感染机理与前景演讲嘉宾：曹晖，江苏吉锐生物技术有限公司，COO 演讲主题：见微知著，放大可能——赛默飞高效液相色谱新品及核酸领域全流程解决方案演讲嘉宾：吴燕娇，赛默飞世尔科技资深应用工程师演讲主题：口服活性环肽类抗血栓药物的从头设计、筛选及合成演讲嘉宾：吴君臣，中国药科大学，教授 ICNS 2026 8月13日论坛一：基础科学与前沿探索演讲主题：阿尔茨海默病药物研发（2016-2025）--从Aβ突破走向精准联合治疗演讲嘉宾：张建忠，卫材（中国）投资有限公司，副总裁兼研发本部本部长演讲主题：神经系统疾病中神经炎症的治疗演讲嘉宾：宋杨，（复星）衡泰生物CEO兼CMO; CEO & CMO of Hygtia Therapeutics 演讲主题：跨越血脑屏障：人源化小鼠平台赋能阿尔茨海默病创新疗法研发演讲嘉宾：贺春辉，百奥赛图（北京）医药科技股份有限公司，药理药效部神经药效组负责人演讲主题：基于神经免疫炎症机制的CNS药物开发：从抑郁症到AD的转化探索演讲嘉宾：包杨欢，普百思生物，创始人&CEO 演讲主题：中枢神经系统药物发现中的挑战与早期评估策略演讲嘉宾：许竣杰，Eurofins Discovery，技术总监圆桌主题： CNS药物递送技术的“终极解决方案”还远吗？CNS创新面临的具体挑战及相应的对策圆桌嘉宾：方群，翼思生物，首席科学官陈小祥，元羿生物，创始人、CEO 方宏亮，晨泰医药，首席研发官章美云，扬子江药业集团创新药物研究院早期研发SVP 尹芝南，暨南大学教授&暨安特博生物董事长演讲主题： SCAD平台：突破中枢神经系统小核酸递送壁垒的高效、持久与安全解决方案演讲嘉宾：李龙承，中美瑞康，创始人、CEO 演讲主题： CNS疾病模型助力创新药物研发演讲嘉宾：陈芙蓉，天津天诚新药评价有限公司，药效研究中心主任演讲主题： CNS领域新药研发的差异化路径演讲嘉宾：李群，博衍（香港）生物医药有限公司，创始人、CEO 演讲主题：从单胺到可塑性，抗抑郁症创新药的新战场演讲嘉宾：闫励，爱思益普，董事长演讲主题：逆转神经退行性病变与脑损伤——开创神经修复医学新篇章演讲嘉宾：陈晨，达尔文生物，首席商务官演讲主题：睡眠调控与功能的分子基础及原创靶点研发演讲嘉宾：王志强，三亚星润境医药控股有限公司，创始人演讲主题： Omega-3 治疗睡眠障碍及其诱导抑郁症的精神免疫学研究进展演讲嘉宾：宋采，深圳市恒海脑健康生物科技有限公司，董事长南方医科大学东莞精神卫生中心教授 8月13日论坛二：产研转化合作与布局演讲主题：酒精使用障碍长效制剂干预策略及临床转化研究演讲嘉宾：曲伟，深圳善康医药科技股份有限公司，副总经理演讲主题：阿尔兹海默病中的生物标志物及其在药物研发中的应用演讲嘉宾：张瑾，先声药业，神经研发副总监演讲主题：神经小鼠模型：让药效照进临床——加速神经新药转化的关键拼图演讲嘉宾：冯睿，药康生物，神经管线首席科学家演讲主题：怎样适应CNS药物开发的新趋势和要求演讲嘉宾：申华琼，纽欧申医药，创始人、首席执行官演讲主题： Closing the Translational Gap in CNS Drug Discovery: Organoids as an Intermediate Platform Bridging In Vitro and In Vivo Systems 演讲嘉宾：尹寅飞，上海睿智医药，资深副总裁演讲主题：神经退行性疾病药物发展 : 从过去看未来演讲嘉宾：陈柏州，加立（深圳）生物科技有限公司，首席执行官演讲主题： CNS药物全球化——跨境合作如何打造创新竞争力演讲嘉宾：边峰，百时美施贵宝，全球药物研发执行总监童岗，武田研发中国及亚太中心副总裁，临床开发负责人李雯佳，罗氏，Director Business Development 廖文胜，绿叶制药集团有限公司，药物化学副总裁管涛，北京正大创新医药有限公司，基金部董事总经理李宁，上海京新生物制药有限公司，CMO 演讲主题：基于非人灵长类模型的神经系统新药药效评价：经验、技术与转化演讲嘉宾：贺烽，湖北天勤生物技术研究院有限公司，副院长演讲主题：设计一款药物，而非设计一个分子—cns药物研发新范式演讲嘉宾：马伟伟，艾斐智药（北京）科技有限公司，联合创始人兼首席商务官（CBO）演讲主题：神经退行性疾病平台与小核酸疗法研发解决方案演讲嘉宾：彭程，药明康德，生物学业务平台助理主任演讲主题：基于神经再生基因疗法治疗重大神经系统疾病演讲嘉宾：陈昱晨，神曦生物，研发副总裁演讲主题：从Aβ清除到精准转化—APOE4/CAA分层下AD药物开发的新策略演讲嘉宾：司马健，中国药科大学，教授演讲主题：溯源靶点：攻克CNS小分子药物研发的 “失败魔咒” 演讲嘉宾：张书理，斯莱普泰，COO 8月14日论坛三：开发策略与研发进展演讲主题：从biib122二期失败重新审视帕金森疾病修饰疗法演讲嘉宾：刘富鑫，和铂医药神经科学平台负责人，COO&CMO 演讲主题： AD抗体类药物在非临床安全性评价中的关注点演讲嘉宾：孔卫青，北京昭衍新药研究中心股份有限公司，毒理部项目负责人演讲主题：神经疾病的未来：基于iPSC的模型构建与药物研发演讲嘉宾：范琪，富士胶片生命科学应用科学家演讲主题：南京脑观象台：自由行为动物脑成像技术驱动的CNS药物研发演讲嘉宾：赵婷，北京大学分子医学南京转化研究院，副院长；南京景瑞康分子医药科技有限公司，总经理演讲主题：开发通用性多肽平台实现血脑屏障穿梭演讲嘉宾：张根卫，晶泰科技，多肽平台负责人演讲主题：高效穿越血脑屏障的RtAAV载体演讲嘉宾：李少勇，杭州嘉因生物，研发VP 演讲主题：神经系统小核酸药物递送技术及产品开发演讲嘉宾：郭炜，中国药科大学，教授；南京诺为基因，创始人演讲主题： PTSD药物研发进展和策略演讲嘉宾：王宗良，药明康德，生物学业务平台副主任演讲主题：蛋白降解创新平台PRODEGRE ATLAS，驱动CNS与炎症突破疗法演讲嘉宾：谭珅，普递瑞（上海）医药有限公司，联合创始人&CEO 由张天蕊，普递瑞（上海）医药有限公司，生物VP代替演讲主题：体内神经元转分化治疗帕金森疾病及抗衰老的最新临床进展演讲嘉宾：周静敏，珠海鲸奇生物，CEO&联合创始人演讲主题：核酸透脑递送技术体系竞争格局与前景展望演讲嘉宾：吴庭鹤，南京科恩里斯生物医药有限公司创始人CEO 8月14日论坛四：成果解析与关键里程碑演讲主题：创新药物递送系统在新药开发中的作用演讲嘉宾：石劲敏，上海汉都医药科技有限公司，副总经理演讲主题： Nav1.7/1.8靶点新药研发演讲嘉宾：王莉，轩竹生物科技股份有限公司，副总经理演讲主题： iPSC衍生细胞模型赋能神经系统药物研发演讲嘉宾：陈诚文，昂朴生物，运营副总演讲主题： CNS新药临床开发的痛点演讲嘉宾：刘平，福贝生物，首席医学顾问演讲主题：抗抑郁药物的最新研究进展及药物开发策略演讲嘉宾：段金金，上海瀚枢生物医药有限公司，研发总监演讲主题： KCNQ2/3开放剂CB03-154在ALS适应症的开发依据和进展演讲嘉宾：陆志红，上海挚盟医药科技有限公司，CMO 演讲主题：具有穿透血脑屏障的放疗增敏剂演讲嘉宾：钟卫，Wayshine Biopharm，创始人、CEO 演讲主题： QP001注射液中美双报临床实践和全球商业化路径演讲嘉宾：俞森，南京清普生物科技有限公司，副总裁演讲主题：延缓神经衰老原创新药的研发演讲嘉宾：陈锦辉，苏州格兰科医药科技有限公司，创始人；国家生物药技术创新中心，首席科学家演讲主题：攻坚「银发海啸」：阿尔茨海默病创新药研发格局及趋势洞察演讲嘉宾：江鹏，丁香园Insight数据库，资深医药行业分析师演讲主题：人福药业全新 Nav1.8 钠通道阻滞剂HW23109分子临床进展演讲嘉宾：房鑫，宜昌人福药业有限责任公司，创新研究中心总监现场集锦 2026 左右滑动查看更多长路漫漫，潜心磨砺，更多会议邀您共话！联系我们咨询更多会议

100 项与齐瑞索韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	齐瑞索韦	-	DB15145

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸道合胞体病毒感染	申请上市	中国	上海爱科百发生物医药技术股份有限公司	2022-12-08
呼吸道合胞病毒肺炎	临床申请批准	美国	上海爱科百发生物医药技术股份有限公司	2026-08-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04231968 (Pubmed \| NEWS) 人工标引	临床3期	呼吸道合胞体病毒感染	188	ziresovir	築膚膚齋範齋艱網範餘(網繭襯鏇願獵製顧範淵) = 鹹糧鹹壓觸壓艱壓顧鹹選衊遞網蓋蓋築襯願簾 (糧遞網積簾構廠廠網膚, -3.9 ~ -3.1) 更多	积极	2025-05-01
				Placebo	築膚膚齋範齋艱網範餘(網繭襯鏇願獵製顧範淵) = 繭窪獵遞衊築網衊糧積選衊遞網蓋蓋築襯願簾 (糧遞網積簾構廠廠網膚, -2.8 ~ -1.7) 更多
NCT04231968 (AIRFLO, Pubmed \| N Engl J Med)	临床3期	呼吸道合胞体病毒感染	244	Ziresovir	膚鹽鏇鏇醖鏇襯觸鬱網(醖觸鹽獵鹹夢夢鏇鹽簾) = Resistance-associated mutations were identified in 15 participants (9%) in the ziresovir group 選鹹鹽窪網觸蓋選獵鏇 (壓鹽構齋餘廠獵襯襯襯 ) 更多	积极	2024-09-26
				Placebo
NCT04231968 (AIRFLO, Literature) 人工标引	临床3期	呼吸道合胞体病毒感染	302	Ziresovir	獵繭醖範淵膚憲餘選蓋(餘顧艱夢憲獵積鬱顧窪) = 繭夢齋獵積窪蓋簾顧蓋願蓋繭衊網獵鹹選顧選 (顧築醖餘築襯積糧醖襯, −3.7 ~ −3.1) 更多	积极	2024-09-25
				Placebo	獵繭醖範淵膚憲餘選蓋(餘顧艱夢憲獵積鬱顧窪) = 膚餘簾鹹壓製廠蓋艱夢願蓋繭衊網獵鹹選顧選 (顧築醖餘築襯積糧醖襯, −3.1 ~ −2.2) 更多